Abstract: The present invention relates generally to the field of crystallography. More particularly, the present invention provides crystalline forms of a complex between granulocyte macrophage-colony stimulating factor (GM-CSF) and its receptor (GM-CSFR). The present invention further provides methods for the design and selection of modulators of GM-CSF/GM-CSFR interaction and signaling as well as signaling of other cytokines.

Abstract: The present invention provides a cytokine-binding domain or portion thereof which binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B?-C? loop of domain 4 of a ?c chain or analogous structure of a cytokine receptor. In another aspect of the invention there is provided a method of identifying a compound having cytokine agonist or antagonist activity, said method including subjecting a potential cytokine agonist and/or cytokine antagonist compound to a cytokine binding domain or portion thereof wherein said domain binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B?-C? loop of domain 4 of a ?c chain or analogous structure of the cytokine receptor; and determining the presence of an agonist or antagonist response of the compound on the activity of a cytokine.

Abstract: The present invention provides a cytokine-binding domain or portion thereof which binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B′-C′ loop of domain 4 of a &bgr;c chain or analogous structure of a cytokine receptor. In another aspect of the invention there is provided a method of identifying a compound having cytokine agonist or antagonist activity, said method including subjecting a potential cytokine agonist and/or cytokine antagonist compound to a cytokine binding domain or portion thereof wherein said domain binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B′-C′ loop of domain 4 of a &bgr;c chain or analogous structure of the cytokine receptor; and determining the presence of an agonist or antagonist response of the compound on the activity of a cytokine.

Abstract: The present invention relates to a binding motif of a receptor. In particular, the binding motif is a cytoplasmic domain associated with stimulation of receptor mediated activities. The present invention further contemplates methods of using the motif in particular for mediating activities of receptors.

Abstract: The present invention relates generally to variant recombinant forms of haemopoietic growth factors useful as antagonists to the corresponding native haemopoietic growth factor and their use in ameliorating aberrant effects caused by the native molecules and in the treatment of tumours and cancers and inflammation.

Abstract: The present invention relates to modified and variant forms of haemopoietic growth factors (HGF) capable of acting as antagonists to the corresponding native haemopoietic growth factors and their use in ameliorating aberrant effects caused by the native molecules. A modified haemopoietic growth factor (HGF) is characterized by being in unglycosylated form and comprising a sequence of amino acids within a first .alpha.-helix wherein one or more exposed amino acids in said first .alpha.-helix having acidic or acidic-like properties are substituted with a basic amino acid residue. The preferred HGF are granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, G-CSF and erythropoietin (EPO).